FUNDACAO PIO XII

Their core work

Hospital de Cancer de Barretos is one of Brazil's largest dedicated cancer treatment and research centers, operating under the Pio XII Foundation and serving patients across the country, including many from underserved rural communities. In EU research projects, their contribution is clinical and translational: they provide access to large, demographically diverse patient cohorts in Latin America, which European partners cannot replicate locally. Their H2020 work focuses on HPV-related cancers — both cervical cancer (screening technology deployment in hard-to-reach populations) and head and neck cancer (survival and genetics studies linking South American and European patient data). They are the rare partner that combines deep clinical volume with real-world experience deploying health interventions in low-resource, community settings.

What they specialise in

How they've shifted over time

Both projects began in 2019, so there is no meaningful temporal gap between them — the keyword shift reflects two parallel research tracks rather than a pivot over time. ELEVATE's keywords center on screening technology and community health delivery (portable, point-of-care, low-cost, hard-to-reach), while HEADSpAcE's keywords shift toward molecular biology and outcomes (survival, genetics). Taken together, this suggests the hospital is deliberately building a two-track HPV-cancer portfolio: one applied and public-health oriented, the other translational and genomics-oriented.

They are consolidating around HPV as a unifying research theme — expanding from population-level cervical screening toward molecular oncology across HPV-driven cancers, which positions them as a South American anchor for future pan-cancer HPV research consortia.

How they like to work

Hospital de Cancer de Barretos participates exclusively as a consortium member — never as coordinator — which is typical for a non-EU institution in Horizon 2020, where administrative and legal lead roles are more naturally held by European partners. Despite holding no lead role, their network is large: 26 distinct partners across 16 countries from just two projects, indicating they are embedded in ambitious, multi-partner international consortia rather than small bilateral collaborations. Working with them means gaining access to Brazilian patient populations and community health infrastructure, with the hospital contributing clinical data and on-the-ground implementation rather than project management.

With 26 consortium partners spanning 16 countries from only two projects, the hospital operates within unusually large international consortia for its project count. Their geographic footprint bridges South America and Europe, which is the core value they bring: a clinical research node on a continent that most EU cancer consortia would otherwise lack access to.

What sets them apart

Hospital de Cancer de Barretos is one of the very few Latin American clinical institutions to participate in Horizon 2020, and that rarity is their primary differentiator — they give European consortia access to large Brazilian patient cohorts, including populations historically underrepresented in cancer genomics research. Their experience deploying screening programs in rural and low-income communities is also genuinely scarce: most EU academic hospitals operate in well-resourced clinical environments and cannot validate tools for low-resource real-world deployment the way Barretos can. For any consortium building a study that needs South American clinical data, multi-ethnic patient diversity, or real-world evidence from constrained health system settings, they are a hard-to-replace partner.

Highlights from their portfolio

• ELEVATE
  Tackles the full pipeline from diagnostic innovation to community deployment — rare for an EU project — by combining HPV genotyping, proteomics, and point-of-care device development with actual field delivery to hard-to-reach women, and Barretos provides the community access that makes this real rather than theoretical.
• HEADSpAcE
  One of the few H2020 projects to explicitly link South American and European patient cohorts for cancer survival and genetics research, with Barretos serving as the anchor site for Latin American data collection.